Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.72 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.72 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.72 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.72 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 6/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155707 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7541760 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14021065 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7545074 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL23343941 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL11446298 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24122546 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6298172 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3065395 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19400314 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822653-B1 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | FACULDADE DE CIENCIAS DA UNIV DE LISBOA (PT) | 2024-06-19 | — | — | EP | disclosed |
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-105792852-B | Glucose-responsive insulin conjugates | 默沙东公司 | 2019-12-10 | — | — | CN | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| CN-105153251-B | A kind of Benzylation method of monose first glycosides | 浙江合糖科技有限公司 | 2018-03-20 | — | — | CN | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170348340-A1 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | UNIVERSIDADE DE LISBOA (50%) (PT) | 2017-12-07 | — | — | US | disclosed |
| US-9775856-B2 | C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents | FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2017-10-03 | — | — | US | disclosed |
| US-5627270-A | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5622936-A | COMPLEX OF SUGAR WITH A PHOSPHORUS AMIDE | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| EP-0369182-B1 | Antitumour saccharide conjugates | DEUTSCHES KREBSFORSCH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0369182-A1 | Antitumour saccharide conjugates | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1990004597-A1 | TUMOR-INHIBITING SACCHARIDE CONJUGATES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 1990-05-03 | — | — | WO | disclosed |
| US-4207413-A | ARTIFICIAL SWEETENER | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | SSTR1 70/4885SSTR2 120/4885SSTR4 51/4885 |
| US-20170348340-A1 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS | IAPP, GBA3, GANAB | SSTR1 3162/4885SSTR2 3805/4885SSTR4 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.